GGrantIndex
← Leaderboards

Paul S. Aisen

Cognition Therapeutics, Inc.

Google Scholar ↗PubMed ↗ORCID ↗
$209,920,520
Attributed
$492,441,602
Total exposure
72
Grants
50
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $70.2M · FY2005–25
$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$566,647,637 · 74

By mechanism

R01$259,802,697 · 11
U24$167,922,818 · 1
U19$82,015,938 · 6
U01$49,917,170 · 1
R56$6,088,879 · 1
M01$900,135 · 54

Top collaborators

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseSiteUnited States National Institutes Of HealthCognitiveFundingDesignClinical TrialsParticipantResourcesPharmaceutical PreparationsResearch PersonnelEnrollmentBiological MarkersPlacebosTau ProteinsRandomizedDementiaDouble-Blind MethodPositron-Emission TomographySafetyImpaired CognitionCognitionAmyloid

Grant awards (152)

Alzheimer's Clinical Trials Consortium (ACTC)$29,438,964
U24 · FY2025 · AG · contact PI
Clinical Core$13,964,403
U19 · FY2025 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$11,955,061
R01 · FY2025 · AG
The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study$6,467,513
R01 · FY2025 · AG
API A4 Alzheimer's Prevention Trial$4,136,602
R01 · FY2025 · AG
Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study$2,072,617
R01 · FY2025 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$28,436,169
U24 · FY2024 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$13,127,747
R01 · FY2024 · AG
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,720,510
R01 · FY2024 · AG · contact PI
API A4 Alzheimer's Prevention Trial$6,538,660
R01 · FY2024 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$2,608,673
R01 · FY2024 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$28,125,414
U24 · FY2023 · AG · contact PI
Clinical Core$14,151,087
U19 · FY2023 · AG · contact PI
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,723,068
R01 · FY2023 · AG · contact PI
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,941,600
R01 · FY2023 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,979,320
R01 · FY2023 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$328,079
R01 · FY2023 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$16,738,113
U24 · FY2022 · AG · contact PI
Clinical Core$10,939,222
U19 · FY2022 · AG · contact PI
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,727,018
R01 · FY2022 · AG · contact PI
API A4 Alzheimer's Prevention Trial$8,413,794
R01 · FY2022 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,943,250
R01 · FY2022 · AG
Long-Term Nicotine Treatment of Mild Cognitive Impairment$6,088,879
R56 · FY2022 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,856,514
R01 · FY2022 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$4,308,552
R01 · FY2022 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$341,233
R01 · FY2022 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$16,802,375
U24 · FY2021 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$14,619,478
R01 · FY2021 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,769,679
R01 · FY2021 · AG · contact PI
Combination anti-amyloid therapy for preclinical Alzheimer's disease$8,732,454
R01 · FY2021 · AG · contact PI
API A4 Alzheimer's Prevention Trial$7,162,340
R01 · FY2021 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$6,944,873
R01 · FY2021 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,980,365
R01 · FY2021 · AG
Long-Term Nicotine Treatment of Mild Cognitive Impairment - Bridge Funding$2,000,351
R01 · FY2021 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$230,541
U24 · FY2021 · AG · contact PI
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$24,533,829
R01 · FY2020 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$16,584,274
U24 · FY2020 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$9,845,298
R01 · FY2020 · AG · contact PI
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,929,565
R01 · FY2020 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment - Bridge Funding$784,085
R01 · FY2020 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$311,154
U24 · FY2020 · AG · contact PI
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$295,100
R01 · FY2020 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$13,976,431
U24 · FY2019 · AG · contact PI
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study$7,047,943
R01 · FY2019 · AG
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$3,981,411
R01 · FY2019 · AG
ADMINISTRATIVE CORE$2,365,884
U19 · FY2019 · AG · contact PI
Alzheimers Clinical Trials Consortium (ACTC)$2,251,991
U24 · FY2019 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,810,887
R01 · FY2019 · AG
INFORMATICS CORE$1,647,744
U19 · FY2019 · AG · contact PI
CLINICAL OPERATIONS CORE$1,497,340
U19 · FY2019 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,137,207
R01 · FY2019 · AG
Alzheimer's Clinical Trials Consortium (ACTC)$344,272
U24 · FY2019 · AG · contact PI
Alzheimer's Clinical Trials Consortium (ACTC)$14,053,120
U24 · FY2018 · AG · contact PI
Combination anti-amyloid therapy for preclinical Alzheimer's disease$9,021,816
R01 · FY2018 · AG · contact PI
API A4 Alzheimer's Prevention Trial$5,670,134
R01 · FY2018 · AG
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$4,967,947
R01 · FY2018 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,797,366
R01 · FY2018 · AG
The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)$630,000
U24 · FY2018 · AG · contact PI
Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease$5,001,194
R01 · FY2017 · AG · contact PI
ADMINISTRATIVE CORE$1,817,862
U19 · FY2017 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,758,065
R01 · FY2017 · AG
CLINICAL OPERATIONS CORE$501,123
U19 · FY2017 · AG · contact PI
INFORMATICS CORE$261,995
U19 · FY2017 · AG · contact PI
The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease$4,020,661
R01 · FY2016 · AG
ADMINISTRATIVE CORE$1,812,321
U19 · FY2016 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,778,118
R01 · FY2016 · AG
CLINICAL OPERATIONS CORE$501,124
U19 · FY2016 · AG · contact PI
INFORMATICS CORE$261,995
U19 · FY2016 · AG · contact PI
Long-term Nicotine Treatment of MCI PA-14-077$150,400
R01 · FY2016 · AG
Long-Term Nicotine Treatment of Mild Cognitive Impairment$1,852,160
R01 · FY2015 · AG
ADMINISTRATIVE CORE$1,744,623
U19 · FY2015 · AG · contact PI
CLINICAL OPERATIONS CORE$486,091
U19 · FY2015 · AG · contact PI
Long-Term Nicotine Treatment of Mild Cognitive Impairment$358,378
R01 · FY2015 · AG
INFORMATICS CORE$262,290
U19 · FY2015 · AG · contact PI
Alzheimer's Disease Cooperative Study$12,480,297
U19 · FY2014 · AG · contact PI
ADMINISTRATIVE CORE$1,793,520
U19 · FY2014 · AG · contact PI
Alzheimer's Disease Cooperative Study$520,000
U19 · FY2014 · AG · contact PI
CLINICAL OPERATIONS CORE$501,125
U19 · FY2014 · AG · contact PI
INFORMATICS CORE$261,996
U19 · FY2014 · AG · contact PI
Alzheimer's Disease Cooperative Study$11,288,568
U19 · FY2013 · AG · contact PI
ADMINISTRATIVE CORE$2,125,707
U19 · FY2013 · AG · contact PI
CLINICAL OPERATIONS CORE$517,721
U19 · FY2013 · AG · contact PI
INFORMATICS CORE$311,900
U19 · FY2013 · AG · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$6,081,533
U01 · FY2012 · AG · contact PI
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease$639,815
R01 · FY2012 · AG · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$5,798,687
U01 · FY2011 · AG · contact PI
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease$648,003
R01 · FY2011 · AG · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$7,233,659
U01 · FY2010 · AG · contact PI
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease$1,216,259
R01 · FY2010 · AG · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$9,638,092
U01 · FY2009 · AG · contact PI
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease$679,814
R01 · FY2009 · AG · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$142,919
U01 · FY2009 · AG · contact PI
ALZHEIMER'S DISEASE SPECIMEN BANK$20,719
M01 · FY2009 · RR · contact PI
AD - NEUROIMAGING$12,087
M01 · FY2009 · RR · contact PI
DHA IN AD$6,907
M01 · FY2009 · RR · contact PI
ADC-03-HBA$6,907
M01 · FY2009 · RR · contact PI
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$1,727
M01 · FY2009 · RR · contact PI
VALPROATE$1,727
M01 · FY2009 · RR · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$10,488,248
U01 · FY2008 · AG · contact PI
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease$2,095,517
R01 · FY2008 · AG · contact PI
ALZHEIMER'S DISEASE SPECIMEN BANK$52,081
M01 · FY2008 · RR · contact PI
AD - NEUROIMAGING$32,818
M01 · FY2008 · RR · contact PI
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$27,112
M01 · FY2008 · RR · contact PI
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE E$24,256
M01 · FY2008 · RR · contact PI
DHA IN AD$12,129
M01 · FY2008 · RR · contact PI
TRIAL OF VALPROATE TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE$12,129
M01 · FY2008 · RR · contact PI
MULTI-CENTER TRIAL TO EVALUATE HOME-BASED ASSESSMENT METHODS FOR AD$7,849
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PILOT STUDY OF HUPERZINE A IN ALZHEIMER'S DISEASE$7,134
M01 · FY2008 · RR · contact PI
PET IMAGING OF BRAIN AMYLOID USING (11C)MES-IMPY$4,281
M01 · FY2008 · RR · contact PI
PF-04494700 IN PARTICIPANTS WITH MILD-TO-MODERATE ALZHEIMERS'S DISEASE$2,853
M01 · FY2008 · RR · contact PI
Alzheimer's Disease Cooperative Study (ADCS)$10,534,032
U01 · FY2007 · AG · contact PI
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$30,194
M01 · FY2007 · RR · contact PI
ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)$26,274
M01 · FY2007 · RR · contact PI
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE E$26,061
M01 · FY2007 · RR · contact PI
PH 3 MULTICTR, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY- ALZHEIMER'S$22,847
M01 · FY2007 · RR · contact PI
A PHASE IIA, MULTICTR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ALZHEIMER'S$17,592
M01 · FY2007 · RR · contact PI
LY2062430:MULT DOSE SAFETY IN SUBJS W/ MILD-MODERATE AD & SINGLE-DOSE HEALTHY$17,592
M01 · FY2007 · RR · contact PI
AD - NEUROIMAGING$14,938
M01 · FY2007 · RR · contact PI
TRIAL OF VALPROATE TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE$13,666
M01 · FY2007 · RR · contact PI
TRIAL OF VALPROATE TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE$13,251
M01 · FY2007 · RR · contact PI
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$13,251
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF HUPERZINE A IN ALZHEIMER'S DISEASE$13,251
M01 · FY2007 · RR · contact PI
EFFECTS OF DONEPEZIL THERAPY ON ELECTROPHYSICOLOGICAL AND NEUROIMAGING MEASUR$12,713
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF HUPERZINE A IN ALZHEIMER'S DISEASE$10,806
M01 · FY2007 · RR · contact PI
PHASE III ALZHEMED- MILD TO MODERATE ALZHEIMER'S DISEASE$8,682
M01 · FY2007 · RR · contact PI
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$4,131
M01 · FY2007 · RR · contact PI
HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW RATE OF COGNITIVE DECLINE$3,178
M01 · FY2007 · RR · contact PI
A MULTICENTER VITAMIN E TRIAL FOR AGING PERSONS WITH DOWN SYNDROME$1,828
M01 · FY2007 · RR · contact PI
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$30,977
M01 · FY2006 · RR · contact PI
EFFECTS OF DONEPEZIL THERAPY ON ELECTROPHYSICOLOGICAL AND NEUROIMAGING MEASUR$29,944
M01 · FY2006 · RR · contact PI
STUDY OF HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF CO$20,651
M01 · FY2006 · RR · contact PI
TRIAL OF VALPROATE TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE$11,358
M01 · FY2006 · RR · contact PI
A PILOT STUDY OF HUPERZINE A IN ALZHEIMER'S DISEASE$10,842
M01 · FY2006 · RR · contact PI
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$6,195
M01 · FY2006 · RR · contact PI
PILOT STUDY OF VITAMIN THERAPY FOR HYPERHOMOCYSTEINEMIA IN ALZHEIMERS DISEASE$2,065
M01 · FY2006 · RR · contact PI
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE E$1,549
M01 · FY2006 · RR · contact PI
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF VALPROATE TO SLOW THE PROGRESSION OF AD$123,251
M01 · FY2005 · RR
TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)$78,591
M01 · FY2005 · RR
SUPPLEMENTS TO REDUCE HOMOCYSTEINE &SLOW RATE OF COGNITIVE DECLINE IN AD$19,414
M01 · FY2005 · RR
PILOT STUDY OF VITAMIN THERAPY FOR HYPERHOMOCYSTEINEMIA IN ALZHEIMER'S DISEASE$19,414
M01 · FY2005 · RR
DONEPEZIL THERAPY ON ELECTROPHYSIOLOGICAL &NEUROIMAGING OF BRAIN ACTIVITY$19,414
M01 · FY2005 · RR
A PILOT STUDY OF HUPERZINE A IN ALZHEIMER'S DISEASE$14,561
M01 · FY2005 · RR
PHASE II :SAFETY &EFFICACY OF NS 2330 IN DEMENTIA OF ALZHEIMER'S TYPE PATIENTS$7,119
M01 · FY2005 · RR
A MULTICENTER VITAMIN E TRIAL FOR AGING PERSONS WITH DOWN SYNDROME$5,178
M01 · FY2005 · RR
ASSESSMENT MEASURES FOR ALZHEIMER'S DISEASE PRIMARY PREVENTION TRIALS$4,853
M01 · FY2005 · RR
PHASE II: CL-758004 W/ ALZHEMED TM IN MILD TO MODERATE ALZHEIMER'S PATIENTS$1,616
M01 · FY2005 · RR
Assessment measures for Alzheimer's disease primary prevention trials$4,560
M01 · FY2004 · RR
High dose supplements to reduce homocysteine &to slow the cognitive decline$3,157
M01 · FY2004 · RR
Pilot study of vitamin therapy for hyperhomocysteinemia in Alzheimers disease$2,455
M01 · FY2004 · RR
Pilot Study of Huperzine A in Alzheimer's Disease$385,198
R01 · FY2003 · AG
Pilot Study of Huperzine A in Alzheimer's Disease$464,411
R01 · FY2002 · AG
Pilot Study of Huperzine A in Alzheimer's Disease$532,765
R01 · FY2001 · AG